Gadolinium-based contrast agents and nephrogenic systemic fibrosis: why did it happen and what have we learned?
J Magn Reson Imaging
; 30(6): 1236-9, 2009 Dec.
Article
em En
| MEDLINE
| ID: mdl-19938035
ABSTRACT
This article addresses two questions about gadolinium-based contrast agents (GBCAs) and nephrogenic systemic fibrosis (NSF) "Why did it happen" and "What have we learned"? It reviews the events leading to the discovery of an association between NSF and GBCAs. Various factors are elucidated that contributed to the delay between the time when GBCA came into widespread clinical use and a link was made with NSF, including use in renal-compromised patients, high-dose magnetic resonance angiography (MRA), lack of documentation and adequate databases, policy and regulatory changes, and an absence of scientific evidence. The authors conclude that the overriding cause was lack of awareness. J. Magn. Reson. Imaging 2009;301236-1239. (c) 2009 Wiley-Liss, Inc.
Texto completo:
1
Coleções:
01-internacional
Base de dados:
MEDLINE
Assunto principal:
Imageamento por Ressonância Magnética
/
Meios de Contraste
/
Dermopatia Fibrosante Nefrogênica
/
Gadolínio
Limite:
Humans
Idioma:
En
Revista:
J Magn Reson Imaging
Assunto da revista:
DIAGNOSTICO POR IMAGEM
Ano de publicação:
2009
Tipo de documento:
Article
País de afiliação:
Estados Unidos